Stifel Maintains Buy on IDEAYA Biosciences, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett maintains a Buy rating on IDEAYA Biosciences and raises the price target from $63 to $68.
September 10, 2024 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Benjamin Burnett has reiterated a Buy rating for IDEAYA Biosciences and increased the price target from $63 to $68, indicating confidence in the company's future performance.
The increase in price target from $63 to $68 by Stifel suggests a positive outlook on IDEAYA Biosciences' future performance. The Buy rating indicates strong confidence from the analyst, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100